TRY NOW

Enhance and accelerate your early stage research with trusted and comprehensive intelligence from Thomson Reuters.

Start your free trial in just two simple steps.

Get your FREE trial

Enrich your discovery science with market leading, manually curated scientific intelligence. Systems Biology, Preclinical, Biomarkers, Chemistry, Biology, and Pharmacology - and everything in between. Covered from the perspective that matters most – yours.
Customer Feedback
Customer Feedback

Annette Bakker, Chief Scientific Officer from CTF, explains the reasons why she likes to work with Thomson Reuters. Currently using MetaCore™ to identify disease treatment options.

Live & Recorded Training

Attend one of our regularly scheduled webinar training sessions for overviews of features, tools, and content – find the schedule here

Free Pathway Maps

Search or browse through a wide range of proprietary multi-step canonical pathway maps here.

Featured News

The latest news from Life Sciences Research
The future of COPD treatment

The future of COPD treatment

Our research shows greater focus on preventative therapies

Translational Medicine

Translational Medicine

Supplement-Size Doses of Antioxidants Hasten Lung Cancer Progression

Tet Proteins Erase Epigenetic Marks

Tet Proteins Erase Epigenetic Marks

It is (reasonably) common knowledge that DNA is written in a simple four-letter code: ACTG. Too simple, actually.

Blog Highlights

Read our latest blog posts

Precision Medicine and National Initiatives: An Update

Since the first human genome was sequenced, there have been big advances in sequencing technologies and costs have been driven down. Today, genomics and other ...

Notable Deals in the Pharmaceutical Industry in Q2 2015

During the 2nd quarter of 2015, Cortellis Competitive Intelligence had 659 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This ...

FDA Paves Way for Symbicort Generics in this Decade

Angel Belmonte Aguirre, Editor at Thomson Reuters, gives an overview of the increased potential of the US generic entry of Symbicort this decade following bioequivalence ...

Whitepapers & Publications

View our recent whitepapers and publications

Biomarkers: An indispensible addition to the drug development toolkit

In this white paper, Thomson Reuters explores the role of biomarkers as evaluative tools in improving clinical research and the ...

THE YEAR'S NEW DRUGS & BIOLOGICS, 2013: PART I

http://dx.doi.org/10.1358/dot.2014.50.1.2116673

Latest on Twitter

Latest on Linked In